‘Jeff can’t help himself’: A frenzied CEO’s push to get depression drugs to market

Jeff Jonas is a 64-year-old longboard-surfing, ketchup-loving bolt of energy. And he's hoping to get new and much-needed depression drugs to market.

CAMBRIDGE, Mass. — For Dr. Jeff Jonas, the desire to understand complex mechanics extends from how drugs reach brain receptors to the design of a well-run clinical trial to the craftsmanship that goes into a first-class watch, of which he owns many.

“This is a Rolex, a new Daytona, which is hard to get,” Jonas was saying of the piece on his wrist the other day, racing through his mile-a-minute, no-need-to-complete-a-sentence explanation. “They have an ultrahard piece of ceramic, which is their big innovation, plus they have a clutch system in the chronograph, which makes it very accurate, so the shape of the clutch, whether it’s vertical or horizontal, it’s all — and some guy does this.”

Jonas himself is the guy in charge of Sage Therapeutics, a company fresh off positive clinical trial results for drugs to treat two forms of depression and pushing ahead with its aim of getting medicines for central nervous system disorders approved.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPsychology
Opinion: In A Medical Emergency, Who In Your Social Network Will Call For Help Quickest?
Applying the "strength of weak ties" theory to medicine, a weakly connected familiar in your social network can be the outside voice of reason who isn't afraid to call for…
STAT3 min read
Why Are Elite Athletes Different Than The Rest Of Us? Take A Look At Their Microbes
Elite athletes really are different from you and me. Or, at least their gut microbes are. Scientists who analyzed stool samples of 15 runners a week before and after they competed in the 2015 Boston Marathon found unusually high levels of one particu
STAT2 min read
AbbVie To Acquire Allergan For $63 Billion In Megamerger Of Pharma Giants
AbbVie said Tuesday it will acquire Allergan for $63 billion — the latest megamerger between two pharma giants seeking new ways to grow.